



HAL
open science

Serious complications and recurrences after pelvic organ prolapse surgery for 2309 women in the VIGI-MESH registry

Xavier Fritel, Renaud de Tayrac, J Keizer, S Campagne-loiseau, M Cosson, P Ferry, X Deffieux, J-p Lucot, L Wagner, P Debodinance, et al.

► **To cite this version:**

Xavier Fritel, Renaud de Tayrac, J Keizer, S Campagne-loiseau, M Cosson, et al.. Serious complications and recurrences after pelvic organ prolapse surgery for 2309 women in the VIGI-MESH registry. *BJOG: An International Journal of Obstetrics and Gynaecology*, 2021, Online ahead of print. <10.1111/1471-0528.16892>. <inserm-03353325>

HAL Id: inserm-03353325

<https://inserm.hal.science/inserm-03353325v1>

Submitted on 24 Sep 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

Serious complications and recurrences after pelvic organ prolapse surgery for 2309 women in the VIGI-MESH registry

Xavier Fritel, Renaud de Tayrac, J Keizer, S Campagne-loiseau, M Cosson, P Ferry, X Deffieux, J-p Lucot, L Wagner, P Debodinance, et al.

► **To cite this version:**

Xavier Fritel, Renaud de Tayrac, J Keizer, S Campagne-loiseau, M Cosson, et al.. Serious complications and recurrences after pelvic organ prolapse surgery for 2309 women in the VIGI-MESH registry. *BJOG: An International Journal of Obstetrics and Gynaecology*, Wiley, 2021, Online ahead of print. 10.1111/1471-0528.16892 . inserm-03353325

HAL Id: inserm-03353325

<https://www.hal.inserm.fr/inserm-03353325>

Submitted on 24 Sep 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Title
2 Serious complications and recurrences after pelvic organ prolapse surgery for 2309 women
3 in the VIGI-MESH registry

4 Authors

5 Xavier Fritel, MD, PhD, 1, 2
6 Renaud de TAYRAC, MD, PhD, 3
7 Joe de Keizer, MSc, 2
8 Sandrine Campagne-Loiseau, MD, 4
9 Michel Cosson, MD, PhD, 5
10 Philippe Ferry, MD, 6
11 Xavier Deffieux, MD, PhD, 7
12 Jean-Philippe Lucot, MD, 8
13 Laurent Wagner, MD, 9
14 Philippe Debodinance, MD, 10
15 Christian Saussine, MD, PhD, 11
16 Anne-Cécile Pizzoferrato, MD, PhD, 12
17 Caroline Carlier-Guérin, MD, 13
18 Thibault Thubert, MD, PhD, 14
19 Laure Panel, MD, 15
20 Pierre-Olivier Bosset, MD, 16
21 Elvis Nkounkou, MD, 17
22 Rajeev Ramanah, MD, PhD, 18
23 Thomas Boisramé, MD, 19
24 Thomas Charles, MD, 20
25 Cyril Raiffort, MD, 21
26 Amélie Charvériat, MD, MSc, 1
27 Stéphanie Ragot, MD, PhD, 2
28 Arnaud Fauconnier, MD, PhD, 22

29 Institutions

30 1. Service de Gynécologie, CHU de Poitiers, Poitiers, France
31 2. Université de Poitiers, INSERM CIC 1402, Poitiers, France
32 3. Service de Gynécologie, CHU Carémeau, Nîmes, France
33 4. Service de Gynécologie, CHU Estaing, Clermont-Ferrand, France
34 5. Service de Gynécologie, CHU de Lille, France
35 6. Service de Gynécologie, CH de La Rochelle, La Rochelle, France
36 7. Service de Gynécologie, APHP Antoine-Béclère, Clamart, France
37 8. Service de Gynécologie, Hôpital Saint-Vincent-de-Paul, Lille, France
38 9. Service d'Urologie, CHU Carémeau, Nîmes, France
39 10. Service de Gynécologie, CH de Dunkerque, Dunkerque, France
40 11. Service d'Urologie, CHU de Strasbourg, Strasbourg, France
41 12. Service de Gynécologie, CHU de Caen, France
42 13. Service de Gynécologie, CH de Châtellerauld, Châtellerauld, France
43 14. Service de Gynécologie, CHU de Nantes, Nantes, France
44 15. Service de Gynécologie, Clinique Beau-Soleil, Montpellier, France
45 16. Service d'Urologie, Hôpital Foch, Suresnes, France

- 46 17. Service de Gynécologie, CH de Béthune, Béthune, France
47 18. Université de Franche-Comté, CHU de Besançon, Besançon, France
48 19. Service de Gynécologie, CHU de Strasbourg, Strasbourg, France
49 20. Service d'Urologie, CHU de Poitiers, Poitiers, France
50 21. Service de Gynécologie, Groupe Hospitalier Diaconesses-Croix-Saint-Simon, Paris, France
51 22. Service de Gynécologie, CHI Poissy-Saint-Germain, Poissy, France

52 Correspondence:

53 Prof. Xavier Fritel, Service de Gynécologie-Obstétrique et Médecine de la Reproduction, 2
54 rue de la Milétrie, CHU de Poitiers, F-86000 Poitiers, France.
55 +33 549 443 360. xavier.fritel@univ-poitiers.fr

56 Running title: Complications after 2309 prolapse surgeries.

57 Manuscript word count: 2680

58

59 Abstract

60 *Objective:* To assess the incidence of serious complications and reoperations for recurrence
61 after pelvic organ prolapse (POP) surgery and compare the three most common types of
62 repair.

63 *Design:* Prospective cohort study using a registry.

64 *Setting:* 19 French surgical centres.

65 *Population:* 2309 women participated between 2017 and 2019.

66 *Methods:* A multivariate analysis including an inverse probability of treatment weighting
67 approach was used to obtain three comparable groups.

68 *Main outcome measures:* Serious complications and subsequent reoperations for POP
69 recurrence

70 *Results:* Median follow-up was 17.6 months. Surgeries were native tissue vaginal repairs
71 (N=504), transvaginal mesh placements (692), and laparoscopic sacropexies with mesh
72 (1113). Serious complications occurred among 52 women (2.3%), and reoperation for POP
73 recurrence was required for 32 (1.4%). At one year, the cumulative weighted incidence of
74 serious complications was 1.8% for native tissue vaginal repair, 3.9% for transvaginal mesh,
75 and 2.2% for sacropexy; while those rates for reoperation for recurrence were respectively
76 1.5%, 0.7%, and 1.1%. Compared with native tissue vaginal repair, the risk of serious
77 complications was higher in the transvaginal mesh group (weighted hazard ratio 3.84, 95% CI
78 2.43-6.08), and the sacropexy group (2.48, 1.45-4.23), while the risk of reoperation for
79 prolapse recurrence was lower in both the transvaginal mesh (0.22, 0.13-0.39) and
80 sacropexy (0.29, 0.18-0.47) groups.

81 *Conclusions:* Our results suggest that native tissue vaginal repairs have the lowest risk of
82 serious complications but the highest risk of reoperation for recurrence. These results are
83 useful for informing women and for shared decision making.

84

85 Keywords: registry, longitudinal study, mesh, pelvic organ prolapse, surgical complication.

86 Tweetable abstract: Laparoscopic sacropexy showed fewer serious complications than
87 transvaginal mesh and fewer reoperations for recurrence than vaginal repair.

88

89 Introduction

90 Pelvic organ prolapse is a frequent disability that leads to surgical repair for around one fifth
91 of all women.¹ About 1.1 woman per 1000 undergoes surgery for this condition in France,
92 and around 3.6-3.8 per 1000 aged 60-79 years in the USA.^{2,3} Information about the risks of
93 adverse effects is essential for choosing the procedure most appropriate to the woman's
94 clinical situation and expectations. To promote shared decision-making, this information
95 must include the frequent or serious complications.⁴

96 The information that surgeons provide before the intervention comes from their own
97 experience and their knowledge of the clinical studies. Surgical trials often include selected
98 and small samples. Subjects included in trials are often younger and at lower risk than their
99 target population.^{5,6} This situation should encourage efforts to complete the results of trials
100 with prospective registries implemented to reflect current clinical practice.^{7,8}

101 The VIGI-MESH registry prospectively collects data about operations performed to treat
102 pelvic organ prolapse and follows them up to track both their serious complications and
103 reoperations for recurrence.⁹ The registry has now been in operation for three years. We
104 anticipate that the incidence of serious complications and of reoperations for recurrence
105 might differ by the type of surgical repair planned (native tissue vaginal repair, transvaginal
106 mesh placement, or laparoscopic sacropexy with mesh). The objective of our analysis was to
107 assess the risks of the different surgical options used in real-world practice for prolapse
108 repair.

109

110 Methods

111 Participation in the VIGI-MESH registry began after the Comité de Protection des Personnes
112 Ouest III (Institutional Review Board) in February 2017 (IDRBC 2017-A000308-45) approved it
113 and it was posted on Clinicaltrial.gov (NCT03052985). The Agence Nationale de Sécurité du
114 Médicament et des produits de santé (national medicines agency) provided funding for the
115 VIGI-MESH registry, but played no role in data collection or analysis, assessment of the
116 complications, or interpretation of the results. The study had no support or involvement by
117 any manufacturer of mesh.

118 Participation was offered to all women undergoing surgery for anterior, apical (uterine or
119 vaginal vault) or posterior vaginal prolapse. Each participating woman received information
120 about the VIGI-MESH registry and consented. Surgeons described each operation on a
121 specific case report form. We checked the data collection by comparing surgeons' reports
122 with mesh deliveries from the hospital pharmacies and the surgical codes of eligible
123 procedures recorded by each hospital's medical data department.⁹

124 This analysis considered three surgical groups: obliterative or vaginal repairs involving native
125 tissue and no mesh (hereafter, vaginal repair), transvaginal placements of mesh (hereafter,
126 transvaginal mesh), and laparoscopic sacropexies, which included colposacropexies (in cases
127 of previous or associated hysterectomy) or colpohysterosacropexies (when the uterus was
128 left in place) that placed mesh by laparoscopy. These procedures are those most frequently
129 used in high-resource countries.¹⁰ The other, rarer surgical procedures (sacropexy by
130 laparotomy, laparoscopy without mesh, and lateral suspensions) were not included in this
131 analysis as they were rare in our registry.⁹ The planned surgical group was used for the
132 analysis; for example, a laparoscopic sacropexy converted to a transvaginal mesh procedure
133 was analysed as a laparoscopic sacropexy.

134 *Outcomes:*

135 In accordance with the design of the registry, the surgeons reported complications and
136 reoperations on a specific form during follow-up. To ensure the completeness of the
137 surgeons' reports (for complications and reoperations), we checked the data collected by
138 each hospital's data department to link and monitor medical events after the index surgery
139 and surveyed the participating women (annual postal questionnaire).⁹ Medical data are

140 analysed as they are received. Queries to surgeons asked them to confirm and detail any
141 serious complications or reoperations when data for these appeared to be missing.

142 We used the Clavien-Dindo classification to define serious complications: cancellation of
143 planned mesh repair due to intraoperative injury or subsequent surgical intervention related
144 to complication (Grade III), life-threatening complication (Grade IV), or woman's death
145 (Grade V).¹¹ Minor adaptations of the classification designated to describe specific POP-
146 surgery complications were those previously used in the PROSPERE trial.¹² Conversion (for
147 example, from laparoscopy to the vaginal route) due to operative difficulties, such as
148 adhesions, was not considered a complication.¹³ The complications analysed here, selected
149 together with the steering committee, were those possibly attributable to the surgical
150 procedure. Reoperation for prolapse recurrence was considered a failure but not a
151 complication. For each complication, the operative files of the index surgery and subsequent
152 procedures were reviewed by two of the authors (XF and AC). At the request of the
153 reviewers we also analysed the risk of reoperation by creating a composite variable including
154 the reoperations for complication of the prolapse surgery and those for recurrence of the
155 prolapse or for de novo urinary incontinence.

156 *Statistical analysis:*

157 Baseline comparisons of the three surgical groups for women's characteristics used ANOVA
158 tests for continuous and Chi-square tests for categorical variables.

159 We used a propensity score approach with inverse probability of treatment weighting to
160 balance the baseline differences between the surgical groups and limit indication bias.^{14,15} A
161 multinomial logistic regression was constructed to estimate each woman's probability of
162 receiving one of the three types of surgeries given her baseline covariates (i.e., the
163 propensity score). Variables of the propensity score model were prespecified before
164 outcome analyses and included age, body mass index, smoking, diabetes, surgical history
165 (hysterectomy, or surgery for stress urinary incontinence or pelvic organ prolapse), physical
166 status score (ASA), menopausal status, and anatomical defect. Stabilized weights were used
167 to estimate the average treatment effect in the entire population, and the extreme weights
168 were truncated.¹⁶ Balance between treatment populations was evaluated by standardised
169 differences of all baseline covariates, with a threshold of 0.1 used to indicate imbalance.¹⁶

170 Survival curves were obtained with the Kaplan-Meier estimator. In the absence of earlier
171 events, we censored events as of 10 December, 2019. Three weighted frailty models — one
172 for serious complications, one for reoperations for POP recurrence, and one for any
173 reoperation (for complications of POP recurrence or stress urinary incontinence) — were
174 used to compare the three surgical groups. The models included a non-parametric
175 estimation of the baseline hazard, a gamma frailty term for the centre effect, and weights
176 that were based on the propensity score.^{17,18}

177 All statistical tests were two-sided, a *P*-value <0.05 was considered significant. A multiple
178 imputation (R mice package) strategy was used to deal with the missing data. We have
179 verified the random character of the missing data; they are indeed missing at random,¹⁹ and
180 found no difference between patients with completely observed data and those with
181 incomplete data; all imputed values fell in the range expected. All statistical analyses were
182 performed with the R statistical package, version 3.6.1 or later (The R Foundation for
183 Statistical Computing, <https://www.R-project.org/>).

184 Patients were not involved in the development of the VIGI-MESH registry. No core outcome
185 sets were used.

186

187 Results

188 Between February 2017 and November 2019, 2309 women underwent a surgical repair for
189 pelvic organ prolapse by 110 surgeons in 19 centres, agreed to participate in the registry and
190 were included in the analysis. We estimate that the surgical procedures included in the
191 analysis represent about 76.6% of eligible procedures for POP repair performed during the
192 study period in the 19 centres (Table S1).

193 The vaginal repair group included 504 women (including 36 with obliterative repairs), the
194 transvaginal mesh group 692, and the laparoscopic sacropexy group 1113 (including 128
195 with robotic assistance; Table S2). Eight women in the laparoscopic sacropexy group needed
196 a conversion (0.7%): three times to a laparotomic sacropexy, twice to laparoscopic lateral
197 attachment, twice to transvaginal mesh, and once to vaginal repair. One or more other
198 surgical procedures were associated with prolapse surgery, including midurethral sling
199 placement and hysterectomy (Table S2).

200 The surgical groups differed in terms of age, body mass index, diabetes, menopausal status,
201 smoking, previous hysterectomy, previous surgery for stress urinary incontinence or for
202 pelvic organ prolapse, and anatomical defect (Table 1). Seven of the 12 covariates in the
203 planned propensity score had weighted maximum standardised differences below 10%,
204 while 5 (age, menopausal status, history of POP surgery, history of hysterectomy, and
205 anatomical anterior defect) exceeded the threshold by a maximum of 4% (Figure S1).
206 Despite the differences observed for the mean age of the surgical groups, the age
207 distribution showed a large overlap between them (Figure S2).

208 Median follow-up was 17.6 months (0.4 to 33.8). Complications of Clavien-Dindo grade III or
209 higher occurred to 52 women (Table 2). During surgery or in the first 48 hours, 7 women had
210 an intraoperative injury, 4 a haemorrhage or haematoma, and 1 a cardiac infarct. From 2
211 days to 2 months, 18 women required surgical treatment of complications (some women
212 had more than one type): 1 had peritonitis, 1 appendicitis, 1 wound dehiscence, 1 bladder
213 retention, 7 a haemorrhage or haematoma, 4 ureteral obstruction, 4 pelvic abscess, 1 severe
214 postoperative pain, and 2 vaginal mesh exposure. Between 2 and 12 postoperative months,
215 20 women required surgical treatment for a complication (5 women had 2 complications
216 each): 11 had vaginal mesh exposure, 1 bladder mesh exposure, 3 severe chronic pain, 2

217 ureteral obstruction, 2 an incisional hernia and 3 a vaginal granuloma. Two women returned
218 to the operating room more than a year after the prolapse surgery: 1 for an incisional hernia,
219 and 1 for toxin injection. Complications necessitated 16 interventions to remove the mesh
220 totally or partially (0.9%).

221 At 12 months the cumulative weighted incidence of serious complications was 1.8% for
222 vaginal repair (95% CI 0-3.9), 3.9% for transvaginal mesh (95% CI 2.0-5.9), and 2.2% for
223 sacropexy (95% CI 1.1-2.6). Compared with the sacropexy group, the risk of serious
224 complications was higher among women in the transvaginal mesh group (Figure 1, Table 3).
225 A concomitant total hysterectomy was associated with a higher risk of complications (Table
226 3). A sensitivity analysis was performed by excluding both complications with debatable
227 imputability (one case of appendicitis and one case of an overactive bladder requiring
228 botulinum toxin); both results remained the same. The analysis limited to the women with
229 an anterior defect found similar and significant hazard ratios (Table S3). Due to a recurrence
230 of the prolapse, a second intervention was required for 32 women (1.4%): 14 after vaginal
231 repair (2.8%), 6 after transvaginal mesh (0.9%), and 12 after sacropexy (1.1%). At 12 months
232 the cumulative weighted incidence of reoperation for prolapse recurrence was 1.5% for
233 vaginal repair (95% CI 0.4-2.5), 0.7% for transvaginal mesh (95% CI 0-1.4), and 1.1% for
234 sacropexy (95% CI 0.3-1.9). Compared with the vaginal repair group, the risk of reoperation
235 for prolapse recurrence was reduced in the transvaginal mesh and sacropexy groups (Figure
236 2, Table 4), with no significant differences between the latter two groups.

237 Postoperative stress incontinence resulted in reoperation for 61 women (2.6%): 6 after
238 vaginal repair (1.2%), 28 after transvaginal mesh (4.0%), and 27 after sacropexy (2.4%).
239 When we considered the composite criterion of all reoperations (for complications,
240 recurrence of prolapse, or postoperative stress incontinence), 124 women underwent
241 reoperations (5.4%): 23 after vaginal repair (4.6%), 48 after transvaginal mesh (6.9%), and 53
242 after sacropexy (4.8%). At 12 months the cumulative weighted incidence of reoperation for
243 complicated prolapse recurrence or stress urinary incontinence was 3.2% for vaginal repair
244 (95% CI 1.0-5.4), 6.9% for transvaginal mesh (95% CI 4.4-9.3), and 5.3% for sacropexy (95% CI
245 3.7-6.9). The comparison between the groups shows a significant difference in favour of the
246 vaginal repair group only if we consider the propensity score (weighted HR, Table S4).

247 The women included in 2017 and 2018 received a postal questionnaire (about complication
248 and recurrence) and 61% of 1575 responded. The responses showed that 96.3% of the
249 serious complications were already listed in the registry as were 94.1% of the reoperations
250 for prolapse recurrence.

251

252 Discussion

253 Main findings

254 We report an analysis of data collected from routine care to compare the short-term efficacy
255 and safety of the three most common surgical procedures for pelvic organ prolapse repair in
256 a population of 2309 women. The events were uncommon: at 1 year the women in the
257 vaginal repair group were exposed to the lowest risk of serious complications and the
258 highest risk of reoperation for recurrence (1.5%), the women in the transvaginal mesh group
259 to the highest risk of serious complications (3.9%) and the lowest risk of reoperation for
260 recurrence (0.7%), and the women in the laparoscopic sacropexy group to an intermediate
261 risk of serious complications (2.2%) and a low risk of reoperation for recurrence (1.1%), as
262 were those in the transvaginal mesh group.

263 Strengths and limitations

264 The strengths of our study are its large prospective registry including 19 centres and
265 numerous surgeons; these features enable the detection of rare events. The analysis covers
266 operations performed in real-life situations: complex clinical situations were not excluded.
267 Indeed, a high proportion of our population would not have been included in a randomised
268 trial, because they were too old or had prolapse recurrence after previous surgery or various
269 comorbidities. The regular and routine verification of the information from the hospitals
270 databases and from the participants is evidence of validity.

271 Our primary outcome was based on a robust criterion, as the modified Clavien–Dindo
272 classification has been found to be a valid and reproducible classification of complications in
273 various surgical domains.^{11,12}

274 Our results must be interpreted considering the absence of randomisation. The surgical
275 groups had different characteristics. It is possible that the type of prolapse influenced the
276 choice of the most appropriate surgical technique. However, we took the women's
277 preoperative characteristics into account with the propensity score to emulate a
278 comparative trial.¹⁴ The data about the construction of the propensity score appear
279 reassuring regarding potential unmeasured confounders that may bias our results. When we
280 consider the variable with the greatest difference between the groups (anterior defect), the
281 results of the analysis limited to the women with an anterior defect were similar to those for

282 all women. Within each surgical group, there were multiple and different surgical
283 procedures. It is probable that some hysterectomies (especially in the vaginal repair group)
284 were expediency hysterectomies performed to facilitate the intervention, whereas the
285 surgeons appeared to avoid hysterectomies for women in the transvaginal mesh group. We
286 were not able to consider some factors that might have promoted prolapse recurrence, such
287 as family history, prolapse stage 3-4, a large genital hiatus or levator ani avulsion.²⁰ These
288 limitations are the price of a "real world" study design, which can introduce variance but
289 limits statistical power.

290 Another limitation is the shortness of the follow-up (median 17 months). However, a Finnish
291 cohort found that most complications of POP surgery occurred within the first two
292 postoperative months.²¹ Five year after transvaginal mesh placement, another study found
293 that 79% of the mesh exposures occurred during the first postoperative year.²²

294 The number of events observed limited the number of explanatory variables we were able to
295 add to the multivariate models. We were unable to specify some technical surgical details
296 (such as the type of mesh or the sutures used), or the experience of both surgeons and
297 centres, which may reduce the risk of complication. Assessing these factors may be useful
298 for improving the procedures or determining if some procedures should be reserved to
299 expert centres.

300 Interpretation

301 Our results about the relative risk of serious complications are similar to earlier comparative
302 studies, reporting fewer complications with vaginal surgery without mesh.^{23,24} The incidence
303 of complications in our registry is lower than that reported in several trials. This difference
304 may be explained by the definition used for complications, which considered only serious
305 Clavien-Dindo complications. The risk of reporting failure seems marginal, as we
306 systematically and regularly verified the information with the hospitals' data departments
307 and with the women. Most participating hospitals are teaching hospital centres specialised
308 in management of recurrent prolapse. This point may explain the low complication rate.

309 Conclusion

310 Of the three types of prolapse repair analysed, native tissue vaginal repair had a higher risk
311 of reoperation for recurrence than the techniques with mesh (transvaginal mesh and

312 sacropexy); and transvaginal mesh has a higher risk of serious complications than the other
313 two (vaginal repair and sacropexy). As concerns about mesh safety abound, our results offer
314 real-world information for women that can enable them to participate in the choice of
315 technique most appropriate for them.

316

317 Disclosure of interests

318 All authors completed the ICMJE uniform disclosure form. XF, JK, SCL, PF, JPL, LW, PD, CS,
319 ACP, CCG, TT, LP, POB, EN, RR, TB, TC, CR, AC, SR, and AF have nothing to disclose. Prof.
320 Renaud de Tayrac reports grants, personal fees or other from Boston Scientific and
321 Coloplast, during the conduct of the study; non-financial support from Wellspect, outside
322 the submitted work. Prof. Michel Cosson reports personal fees from Boston Scientific,
323 Coloplast, Promedon, and AMI, outside the submitted work. Prof. Xavier Deffieux reports
324 personal fees or other from Urgo-Tech, Coloplast, Allergan, Laborie, Hologic, Sanofi, and
325 Nanobiotics, outside the submitted work.

326 Contribution to authorship

327 Study concept and design: Fritel, Fauconnier, Ragot.
328 Acquisition of data: Fritel, de Tayrac, Campagne-Loiseau, Cosson, Ferry, Hummel, Deffieux,
329 Lucot, Wagner, Debodinance, Saussine, Pizzoferrato, Carlier-Guérin, Thubert, Panel, Bosset,
330 Nkounkou, Ramanah, Boisramé, Charles, Bressler, Charvériat, Raiffort, Fauconnier.
331 Analysis and interpretation of data: Fritel, Fauconnier, de Keizer, Ragot.
332 Drafting of the manuscript: Fritel, Fauconnier, Ragot.
333 Statistical analysis: Fritel, de Keizer, Ragot.
334 Obtaining funding: Fritel.
335 Xavier Fritel had full access to all the data in the study and takes responsibility for the
336 integrity of the data and the accuracy of the data analysis. He attests that all listed authors
337 meet authorship criteria and that no others meeting the criteria have been omitted.
338 We affirm that our manuscript is an honest, accurate and transparent report of the VIGI-
339 MESH registry; that no important aspects of the registry have been omitted; and that any
340 discrepancies from the registry as originally planned and registered have been explained.

341 Details of ethics approval

342 Our study complies with French law. The Institutional Review Board (Comité de Protection
343 des Personnes Ouest III) approved the protocol on 9 February 2017 (IDRBC 2017-A000308-
344 45), and the study was registered by the national data protection authority (Commission
345 Nationale Informatique et Libertés, CNIL) on 16 August 2017 (DR-2017-245).

346 Funding

347 The national medicines agency (Agence Nationale de Sécurité du Médicament et des
348 produits de santé, ANSM) provided the funding for the study, but played no role in data
349 collection or analysis, assessment of the complications, or interpretation of the results.

350 Acknowledgements:

351 We thank Lucie Merlet (CHU de Poitiers), Aurélie Comptour (CHU Carémeau), Florence
352 Tartarin (CHU de Poitiers), Elodie Migault (CHU de Poitiers), and Pierre-Jean Saulnier
353 (Université de Poitiers) for their support or contribution to collecting and cleaning the data.
354 We thank Jo Ann Cahn for the editing (CHU de Poitiers).

355 We thank the 110 surgeons of the VIGI-MESH Group who enrolled patients into the registry:
356 Adnan Aboukassem, Chérif Akladios, Emmanuelle Arsène, Jean-Sébastien Aucouturier,
357 Georges Bader, Emmanuel Bailly, Jean-Jacques Baldauf, Stéphanie Bartolo, Marie-Line
358 Barussaud, Fanny Béchard, Simon Bernardeau, Clément Biscans, Thomas Boisramé, Deepak
359 Boodhun, Pierre-Olivier Bosset, Revaz Botchorishvili, Michel Boukaram, Aude Brams, Laurent
360 Bressler, Clément Bruhat, Sandrine Campagne-Loiseau, Michel Canis, Caroline Carlier-Guérin,
361 Victor Cavillon, Olivier Celhay, Thomas Charles, Amélie Charvériat, Armand Chevrot, Pierre
362 Collinet, Arnaud Cornille, Michel Cosson, Pierre Costa, Christophe Courtieu, Laurent
363 Courtois, Sandra Curinier, Eric Darnis, Renaud de Tayrac, Philippe Debodinance, Xavier
364 Deffieux, Pierre-Olivier Delpech, Véronique Delporte, Anne Dubois, Emilie Faller, Brigitte
365 Fatton, Arnaud Fauconnier, Philippe Ferry, Cécile Féyeux, Xavier Fritel, Victor Gabriele, Pierre
366 Gadonneix, Olivier Garbin, Florent Genty, Géraldine Giraudet, Pascale Gres, Pauline
367 Gueudry, Jean-François Haab, Audrey Hedde, Aline Host, Michel Hummel, Estelle Jean dit
368 Gautier, Aminata Kane, Sophie Le Gouic, Isabelle Le Teuff, Gil Lebreton, Lise Lecointre,
369 Grégoire Léon, Jean-Philippe Lucot, Yolande Maisonnette, Lucile Martin, Aurore Marx, Pascal
370 Mouracade, Elvis Nkounkou, Corinne Palamara, Laure Panel, Petit Nicolas, Caroline
371 Pettenati, Laurence Peyrat, Pierre Pillot, Anne-Cécile Pizzoferrato, Jean-Luc Pouly, Clothilde
372 Poupon, Michel Prudhomme, Benoît Rabishong, Rajeev Ramanah, Hélène Ricard, Jérémie
373 Ripoché, Géraldine Rivaux, Jennifer Salerno, Delphine Salet-Lizée, Richard Sarfati, Maxence
374 Sarradin, Christian Saussine, Elodie Schuller, An Segaert, François Stoll, Yannick Thirouard,
375 Thibault Thubert, Caroline Trichot, Mélusine Turck, David Vandendriessche, Edouard Vaucel,
376 Sarah Vieillefosse, Anne Villot, Denis Vinatier, Etienne Vincens, Marie Vinchant, Béatrice
377 Vinson-Bonnet, Laurent Wagner, Soraya Wapler, and Sophie Warembourg.

378

- 1 Smith FJ, Holman CD, Moorin RE, Tsokos N. Lifetime Risk of undergoing surgery for pelvic organ prolapse. *Obstet Gynecol* 2010;116:1096-100.
- 2 Subramanian D, Szwarzensztejn K, Mausekopf JA, Slack MC. Rate, type, and cost of pelvic organ prolapse surgery in Germany, France, and England. *Eur J Obstet Gynecol Reprod Biol* 2009;144:177-81.
- 3 Wu JM, MD, Matthews CA, Conover MM, Pate V, Funk MJ. Lifetime Risk of Stress Incontinence or Pelvic Organ Prolapse Surgery. *Obstet Gynecol* 2014;123:1201-6.
- 4 Barber MD. Mesh use in surgery for pelvic organ prolapse, Despite many advances, outcomes after surgery remain far from perfect. *BMJ* 2015;350:h2910
- 5 Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, Arefalk G, Frick M, Alfredsson J, Nilsson L, Ravn-Fischer A, Omerovic E, Kellerth T, Sparv D, Ekelund U, Linder R, Ekström M, Lauerermann J, Haaga U, Pernow J, Östlund O, Herlitz J, Svensson L; DETO2X-SWEDEHEART Investigators. Oxygen Therapy in Suspected Acute Myocardial Infarction. *N Engl J Med* 2017;377:1240-9.
- 6 Lindsay WA, Murphy MM, Almghairbi DS, Moppett IK. Age, sex, race and ethnicity representativeness of randomised controlled trials in peri-operative medicine. *Anaesthesia* 2020;75:809-15.
- 7 Rimmer A. Vaginal mesh procedures need compulsory register, says royal college. *BMJ* 2018;360:k586.
- 8 Fritel X. Evidence about surgical revision for MUS complications will come from large retrospective cohorts and prospective registers. *BJOG* 2020;127:1034.
- 9 Fritel X, Campagne-Loiseau S, Cosson M, Ferry P, Saussine C, Lucot JP, Salet-Lizee D, Barussaud ML, Boisramé T, Carlier-Guérin C, Charles T, Debodinance P, Deffieux X, Pizzoferrato AC, Curinier S, Ragot S, Ringa V, de Tayrac R, Fauconnier A. Complications after pelvic floor repair surgery (with and without mesh): short-term incidence after 1873 inclusions in the French VIGI-MESH registry. *BJOG* 2020;127:88-97.
- 10 Haya N, Baessler K, Christmann-Schmid C, de Tayrac R, Dietz V, Guldberg R, Mascarenhas T, Nusller E, Ballard E, Ankardal M, Boudemaghe T, Wu JM, Maher CF. Prolapse and continence surgery in countries of the Organization for Economic Cooperation and Development in 2012. *Am J Obstet Gynecol* 2015;212:755.e1-27
- 11 Dindo D, Demartines N, Clavien PA. Classification of surgical complications. *Ann Surg* 2004;240:205-13.
- 12 Lucot JP, Cosson M, Bader G, Debodinance P, Akladios C, Salet-Lizée D, Delporte P, Savary D, Ferry P, Deffieux X, Campagne-Loiseau S, de Tayrac R, Blanc S, Fournet S, Wattiez A, Villet R, Ravit M, Jacquelin B, Fritel X, Fauconnier A. Safety of Vaginal Mesh Surgery Versus Laparoscopic Mesh Sacropexy for Cystocele Repair: Results of the Prosthetic Pelvic Floor Repair Randomized Controlled Trial. *Eur Urol* 2018;74:167-76.
- 13 Twijnstra AR, Blikkendaal MD, van Zwet EW, Jansen FW. Clinical relevance of conversion rate and its evaluation in laparoscopic hysterectomy. *J Minim Invasive Gynecol* 2013;20:64-72.
- 14 Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiology* 2000;11:550-60
- 15 Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. *Stat Med* 2004;23:2937-60.
- 16 Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. *Stat Med* 2010;29:2137-48.
- 17 Duchateau L, Janssen P, Lindsey P, Legrand C, Nguti R, Sylvester R. The shared frailty model and the power for heterogeneity tests in multicenter trials. *Computational Statistics & Data Analysis* 2002;40:603-20.
- 18 Gutierrez RG. Parametric frailty and shared frailty survival models. *The Stata Journal* 2002;2:22-44.
- 19 Nguyen C, Carlin JB, Lee KJ. Model checking in multiple imputation: an overview and case study. *Emerg Themes Epidemiol* 2017;14:8.
- 20 Friedman T, Eslick GD, Dietz HP. Risk factors for prolapse recurrence: systematic review and meta-analysis. *Int Urogynecol J* 2018;29:13-21.
- 21 Wihersaari O, Karjalainen P, Tolppanen A-M, Mattsson N, Jalkanen J, Nieminen K. Complications of Pelvic Organ Prolapse Surgery in the 2015 Finnish Pelvic Organ Prolapse Surgery Survey Study. *Obstet Gynecol* 2020;136:1135-44.
- 22 Jacquelin B, Hinoul P, Gauld J, Fatton B, Rosenthal C, Clavé H, Garbin O, Berrocal J, Villet R, Salet-Lizée D, Debodinance P, Cosson M. Total transvaginal mesh (TVM) technique for treatment of pelvic organ prolapse: a 5-year prospective follow-up study. *Int Urogynecol J* 2013;24:1679-86.
- 23 Siddiqui NY, Cara L, Grimes CL, Casiano ER, Abed HT, Jeppson PC, Olivera CK, Sanses TV, Steinberg AC, South MM, Balk EM, Sung VW. Mesh Sacrocolpopexy Compared With Native Tissue Vaginal Repair, A Systematic Review and Meta-analysis. *Obstet Gynecol* 2015;125:44-55.

Figure and table legends

Figure 1. Kaplan-Meier curve free of serious complication (Clavien-Dindo grade III or more) as a function of time (months) and of surgical group (2309 women).

Figure 2. Kaplan-Meier curve free of reoperation for prolapse recurrence as a function of time (months) and of surgical group (2309 women).

Table 1. Women's baseline characteristics at the time of the index surgery for pelvic organ prolapse (N= 2309). Comparison between surgical groups with ANOVA tests for continuous and Chi-square tests for categorical variables.

Table 2. Description of serious complications (Clavien-Dindo Grade III or more) among 52 women by type, time to revision after POP surgery, and type of care for complication (some women may have more than one type of complication).

Table 3. Risk factors for serious complication (Clavien-Dindo grade III or more). Frailty model with centre as a random effect (N= 2309).

Table 4. Risk factors for reoperation for prolapse recurrence. Frailty model with centre as a random effect (N= 2309).

Online supporting information

Figure S1. Standardized differences between surgical groups before and after adjustment.

Figure S2. Age distribution in each surgical group.

Table S1. Detail of inclusions in each centre.

Table S2. Surgical procedures for pelvic organ prolapse (N= 2309).

Table S3. Risk factors for serious complication after POP surgery in women with preoperative anterior defect (N= 1836).

Table S4. Risk factors for reoperation for serious complication, prolapse recurrence, or stress urinary incontinence. Frailty model with centre as a random effect (N= 2309).

Table 1. Women's baseline characteristics at the time of the index surgery for pelvic organ prolapse (N= 2309). Comparison between surgical groups with ANOVA tests for continuous and Chi-square tests for categorical variables.

| Baseline characteristics | | Vaginal repair N= 504 | Transvaginal mesh N= 692 | Laparoscopic sacropexy N= 1113 |
|--------------------------|------------------------------------------------|--------------------------|-----------------------------|-----------------------------------|
| | Age, mean (sd), md= 2 | 67.0 (13.2) | 69.5 (7.6) | 61.8 (10.4) |
| | BMI, mean (sd), md= 12 | 26.2 (4.9) | 26.4 (4.5) | 25.2 (4.0) |
| | Smoking, (n %), md= 39 | 33 (6.5) | 34 (4.9) | 90 (8.0) |
| | Diabetes, n (%), md= 28 | 48 (9.5) | 82 (11.8) | 74 (6.6) |
| | Menopausal status, n (%), md= 7 | 433 (85.9) | 679 (98.1) | 896 (80.5) |
| | Physical status score (ASA), mean (sd), md= 82 | 1.8 (0.6) | 1.9 (0.6) | 1.7 (0.6) |
| | Hysterectomy, n (%), md= 18 | 132 (26.2) | 145 (21.0) | 140 (12.6) |
| Surgical history | SUI surgery, n (%), md= 27 | 64 (12.7) | 77 (11.1) | 71 (6.4) |
| | POP surgery, n (%), md= 34 | 111 (22.0) | 151 (21.8) | 136 (12.2) |
| | Anterior, n (%), md= 2 | 254 (50.4) | 616 (89.0) | 965 (86.7) |
| Anatomical defect | Apical, n (%), md= 2 | 255 (50.6) | 429 (62.0) | 754 (67.8) |
| | Posterior, n (%), md= 2 | 309 (61.3) | 271 (39.2) | 425 (38.2) |

Significant differences between groups for each characteristic with $P < 0.0001$ except smoking ($P = 0.03$) and diabetes ($P = 0.0008$).

sd: standard deviation; md: number of missing data; BMI = body mass index; ASA = American Society of Anaesthesiologists patient classification status; SUI = stress urinary incontinence; POP = pelvic organ prolapse

Table 2. Description of serious complications (Clavien-Dindo Grade III or more) among 52 women by type, time to revision after POP surgery, and type of care for complication (some women may have more than one type of complication).

| Grade III or IV complication, n (%) | Vaginal repair N= 504 | Transvaginal mesh N= 692 | Laparoscopic sacropexy N= 1113 | Overall N= 2309 |
|--------------------------------------------|--------------------------|--------------------------------|--------------------------------------|--------------------|
| Intraoperative injury | - | 5 (0.7) | 2 (0.2) | 7 (0.3) |
| Cardiac infarct | 1 (0.2) | - | - | 1 (0.0) |
| Haemorrhage/haematoma | 4 (0.8) | 6 (0.9) | 1 (0.1) | 11 (0.5) |
| Visceral complication | - | - | 3 (0.3) | 3 (0.1) |
| Pelvic abscess | - | 2 (0.3) | 2 (0.2) | 4 (0.2) |
| Retention or obstructed micturition | - | 2 (0.3) | 1 (0.1) | 3 (0.1) |
| Overactive bladder | - | 1 (0.1) | 1 (0.1) | 2 (0.1) |
| Ureteral obstruction | 1 (0.2) | 4 (0.6) | 1 (0.1) | 6 (0.3) |
| Mesh exposure | - | 9 (1.3) | 5 (0.4) | 14 (0.8)* |
| Vaginal granuloma | 1 (0.2) | 2 (0.3) | - | 3 (0.1) |
| Incisional hernia or dehiscence | - | - | 4 (0.4) | 4 (0.4)* |
| Other severe postoperative or chronic pain | 1 (0.2) | - | 3 (0.3) | 4 (0.2) |
| Time to revision | | | | |
| T1: 0 to 48 hours | 3 (0.6) | 7 (1.0) | 2 (0.2) | 12 (0.5) |
| T2: day 2 to month 2 | 3 (0.6) | 7 (1.0) | 8 (0.7) | 18 (0.8) |
| T3: month 2 to month 12 | 1 (0.2)* | 12 (1.7)* | 7 (0.6)* | 20 (0.9)* |
| T4: > 12 months | - | - | 2 (0.3)* | 2 (0.1)* |
| Care for complication | | | | |
| Mesh placement cancelled | - | 4 (0.6) | 2 (0.2) | 6 (0.3)* |
| Intensive care unit | 1 (0.2) | 2 (0.3) | - | 3 (0.1) |
| Surgery for haemostasis/drainage | 4 (0.8) | 6 (0.9) | 1 (0.1) | 11 (0.5) |
| Appendicitis/peritonitis surgical cure | - | - | 2 (0.2) | 2 (0.1) |
| Mesh surgical ablation | - | 9 (1.3) | 7 (0.6) | 16 (0.9)* |
| Upper urinary tract surgical procedure | - | 2 (0.3) | 1 (0.1) | 3 (0.1) |
| Stitch surgical removal | 1 (0.2) | 1 (0.1) | - | 2 (0.1) |
| Vaginal surgical revision | 1 (0.2) | 5 (0.7) | 1 (0.1) | 7 (0.3) |
| Hernia or dehiscence surgical repair | - | - | 4 (0.4) | 4 (0.4)* |
| Pudendal surgical infiltration | - | - | 1 (0.1) | 1 (0.0) |
| Bladder botulinum toxin injection | - | - | 1 (0.1) | 1 (0.0) |
| Reoperation for serious complication | 6 (1.2) | 21 (3.0) | 17 (1.5) | 44 (1.9) |
| Overall (Grade III and IV complications) | 7 (1.4) | 26 (3.8) | 19 (1.7) | 52 (2.3) |

* related to the number of women at risk.

Table 3. Risk factors for serious complication (Clavien-Dindo grade III or more). Frailty model with centre as a random effect (N= 2309)

| Risk factor | | Non-weighted HR (95% CI) | Weighted* HR (95% CI) |
|--------------------------|------------------------|-----------------------------|--------------------------|
| | Vaginal repair | 1 | 1 |
| Surgical group | Transvaginal mesh | 3.21 (1.35 to 7.62) | 3.84 (2.43 to 6.08) |
| | Laparoscopic sacropexy | 1.61 (0.64 to 4.07) | 2.48 (1.45 to 4.23) |
| Concomitant procedure | Total hysterectomy | 2.48 (1.15 to 5.34) | 4.13 (2.75 to 6.21) |
| | Midurethral sling | 1.26 (0.59 to 2.67) | 0.88 (0.54 to 1.43) |

HR = hazard ratio; CI = confidence interval.

*Weights based on the propensity score which included age, body mass index, smoking, diabetes, surgical history (hysterectomy, or surgery for stress urinary incontinence or pelvic organ prolapse), physical status score (ASA), menopausal status, and anatomical defect.

Exclusion of the two complications with arguable imputability (one case of appendicitis and one case of overactive bladder needing botulinum toxin) did not change the results (weighted HR for transvaginal mesh 3.76, 95% CI 2.38 to 5.95 and for laparoscopic sacropexy 2.23, 95% CI 1.29 to 3.84).

Table 4. Risk factors for reoperation for prolapse recurrence. Frailty model with centre as a random effect (N= 2309)

| Risk factor | | Non-weighted HR (95% CI) | Weighted* HR (95% CI) |
|--------------------------|------------------------|-----------------------------|--------------------------|
| | Vaginal repair | 1 | 1 |
| Surgical group | Transvaginal mesh | 0.18 (0.07 to 0.47) | 0.22 (0.13 to 0.39) |
| | Laparoscopic sacropexy | 0.23 (0.10 to 0.50) | 0.29 (0.18 to 0.47) |
| Concomitant procedure | Total hysterectomy | 0.14 (0.02 to 1.06) | 0.06 (0.01 to 0.27) |
| | Midurethral sling | 0.45 (0.14 to 1.50) | 0.59 (0.32 to 1.09) |

HR = hazard ratio; CI = confidence interval.

*Weights based on the propensity score which included age, body mass index, smoking, diabetes, surgical history (hysterectomy, or surgery for stress urinary incontinence or pelvic organ prolapse), physical status score (ASA), menopausal status, and anatomical defect.




Figure 1. Kaplan-Meier curve free of serious complication (Clavien-Dindo grade III or more) as a function of time (months) and of surgical group (2309 women).




Figure 2. Kaplan-Meier curve free of reoperation for prolapse recurrence as a function of time (months) and of surgical group (2309 women).